SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Stoke Therapeutics, Inc. (STOK) News

Follow Stoke Therapeutics, Inc. (STOK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol STOK Asset equity Sector Markets 90 days 16 Last 26.78 Updated Nov 05, 2026, 06:28 PM UTC Open live news feed Open STOK chart & news
L Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: FMR LLC Filed on: November 5, 20 EQUITY | Nov 05, 2026, 06:28 PM UTC M STOK Reports Fiscal Q3 Net Loss STOK reported a fiscal 2026 third-quarter net loss attributable to shareholders, down 462.92% year over year. Basic EPS was negative. EQUITY | Nov 04, 2026, 10:58 AM UTC M Stoke Therapeutics Reports Third-Quarter 2026 Results Revenue rose 5.9% year over year to $11.3 million. Net loss widened to $73.6 million from $38.3 million, and diluted loss per share was $(1.08) versus $(0.65). EQUITY | Nov 03, 2026, 09:12 PM UTC M Stoke Therapeutics Reports Third-Quarter Loss of $73.6 Million EQUITY | Oct 29, 2026, 08:15 PM UTC M Stoke Therapeutics Reports Q3 Revenue of $11.3 Million Q3 revenue was $11.3 million, versus a FactSet estimate of $8.2 million. EQUITY | Oct 29, 2026, 08:12 PM UTC M Stoke Reports Q3 Results, Plans Zorevunersen NDA in H2 2027 Stoke said its Phase 3 EMPEROR trial remains on track, with about 110 of 162 patients at Week 28 and about 20 at Week 52; all continued into the open-label extension. The company plans a Phase 3 data readout in Q3 2027. EQUITY | Oct 29, 2026, 08:02 PM UTC M Stoke Therapeutics Reports Third-Quarter Loss of $1.08 Per Share EQUITY | Oct 29, 2026, 08:01 PM UTC L Weekly Recap: Zorevunersen 2028 approval goal and Edward Kaye retirement Stoke Therapeutics, Inc. (NASDAQ:STOK) said its antisense therapy zorevunersen aims to boost NaV1.1 in brain cells for a disease—modifying Dravet syndrome treatment with approval targeted around early 2028, as director E NEWS | Sep 28, 2026, 11:06 AM UTC L Stoke Therapeutics names Alexander (Bo) Cumbo to board after Dr. Edward Kaye resignation Stoke Therapeutics appointed Alexander (Bo) Cumbo to its Board as a Class III director, effective September 23, 2026, following the resignation of Edward M. Kaye, M.D.Original SEC Filing: Stoke Therapeutics, Inc. [ STOK REGULATION | Sep 25, 2026, 08:15 PM UTC L Stoke Therapeutics, Inc. (STOK) Adds Bo Cumbo to Board Stoke Therapeutics appointed Bo Cumbo to its Board of Directors as Edward Kaye, M.D., retires from the Board and will advise during the transition. The move adds commercial expertise as Stoke advances zorevunersen toward REGULATION | Sep 23, 2026, 08:01 PM UTC L Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in REGULATION | Sep 23, 2026, 08:01 PM UTC M STOK Phase III Dravet and sustained seizure reduction support milestones STOK says a phase III Dravet syndrome readout is expected within 12 months and progress continues in ADOA trials. Zorevunersen reports sustained 75% seizure reduction plus functional gains, with OLE data supporting long- EQUITY | Sep 09, 2026, 06:35 PM UTC M STOK Phase III Dravet therapy reports durable 75%+ seizure reduction Long-term data for a Phase III Dravet syndrome therapy show sustained 75%+ seizure reduction and functional gains. The pivotal EMPEROR trial is fully enrolled, with endpoints spanning seizures and cognitive improvements. EQUITY | Sep 09, 2026, 06:08 PM UTC L Stoke and Biogen present long-term Zorevunersen data at EEC Stoke Therapeutics and Biogen announced presentations of long-term clinical data supporting the disease-modifying potential of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy GEOPOLITICS | Sep 03, 2026, 11:30 PM UTC L Stoke Therapeutics to present at Cantor Global Healthcare Conference Stoke Therapeutics, Inc. (STOK) said it will present at the Cantor Global Healthcare Conference. EQUITY | Sep 02, 2026, 12:00 PM UTC L Stoke and Biogen to present Zorevunersen clinical data at EEC Stoke Therapeutics and Biogen announced presentations of clinical data from studies of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in September. GEOPOLITICS | Sep 01, 2026, 11:30 AM UTC L STOK initiated Overweight with $40.00 price target at JPMorgan Hammerstone MarketTalk reports that JPMorgan initiated coverage of STOK with an Overweight rating and a $40.00 price target. EQUITY | Aug 21, 2026, 11:58 AM UTC L Stoke Therapeutics Completes Enrollment Of 162 Patients Into Phase 3 EMPEROR Study Of Zorevunersen; Co Plans To Initiate Rolling NDA Submiss Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second ha REGULATION | Jun 30, 2026, 12:10 PM UTC